Dagogo-Jack, Samuel http://orcid.org/0000-0001-5318-9677
Pratley, Richard E http://orcid.org/0000-0002-2912-1389
Cherney, David Z I
McGuire, Darren K
Cosentino, Francesco
Shih, Weichung J
Liu, Jie
Frederich, Robert
Mancuso, James P
Raji, Annaswamy
Gantz, Ira
Clinical trials referenced in this document:
Documents that mention this clinical trial
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
https://doi.org/10.1136/bmjdrc-2021-002484
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Ertugliflozin and Slope of Chronic eGFR
https://doi.org/10.2215/cjn.01130121
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
https://doi.org/10.1007/s13300-021-01033-x
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
https://doi.org/10.1080/14740338.2019.1626823
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
https://doi.org/10.1080/13696998.2018.1562817
An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
https://doi.org/10.1080/13543784.2019.1655539
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease
https://doi.org/10.1161/circulationaha.120.050255
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (Not applicable; general funding of clinical trial)
Pfizer Inc., New York, NY, USA (Not applicable; general funding of clinical trial)